CLINICAL TRIALS PROFILE FOR TETRABENAZINE
✉ Email this page to a colleague
All Clinical Trials for TETRABENAZINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00219804 ↗ | Efficacy and Safety of Tetrabenazine in Chorea | Completed | Prestwick Pharmaceuticals | Phase 3 | 1969-12-31 | The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo |
| NCT00362804 ↗ | Tetrabenazine for Partial Responders | Completed | Stanley Medical Research Institute | N/A | 2002-02-01 | Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action underlying antipsychotic effect Hypothesis/Objectives of the Study: Tetrabenazine, through its pre-synaptic action, should augment the post-synaptic effects of an antipsychotic. Background and Rationale for the study: Preliminary evidence that other amine-depleting agents e.g., reserpine, can induce such an effect |
| NCT00362804 ↗ | Tetrabenazine for Partial Responders | Completed | Centre for Addiction and Mental Health | N/A | 2002-02-01 | Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action underlying antipsychotic effect Hypothesis/Objectives of the Study: Tetrabenazine, through its pre-synaptic action, should augment the post-synaptic effects of an antipsychotic. Background and Rationale for the study: Preliminary evidence that other amine-depleting agents e.g., reserpine, can induce such an effect |
| NCT00632645 ↗ | Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride | Completed | Assistance Publique - Hôpitaux de Paris | Phase 3 | 2009-04-01 | Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade. The disease progression is classically characterized by a cognitive deterioration (cortical-frontal dementia), motor disorders (associating chorea, dystonia and bradykinesia), psychiatric disturbances (combining depression and irritability) and metabolic disorder (cachexia). The disease is fatal within 15 to 20 years in most patients. HD has no cure. Neuroleptics are the main drug used and the only to demonstrate its efficacy on chorea in clinical trials. But neuroleptics have also beneficial and adverse effects on other disease characteristics (motor, psychiatric, cognitive or metabolic). Their profile between beneficial and adverse effects could be different according the neuroleptics and their classification. The aim of this study is to compare beneficial and adverse effects of 3 different neuroleptics in HD. |
| NCT00642057 ↗ | Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements | Available | Christine Hunter | 1969-12-31 | Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements). | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TETRABENAZINE
Condition Name
Clinical Trial Locations for TETRABENAZINE
Trials by Country
Clinical Trial Progress for TETRABENAZINE
Clinical Trial Phase
Clinical Trial Sponsors for TETRABENAZINE
Sponsor Name
